相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A Sustained Virologic Response Reduces Risk of All-Cause Mortality in Patients With Hepatitis C
Lisa I. Backus et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2011)
Eradication of Hepatitis C Virus Reduces the Risk of Hepatocellular Carcinoma in Patients with Compensated Cirrhosis
Jose Velosa et al.
DIGESTIVE DISEASES AND SCIENCES (2011)
Increasing Prevalence of HCC and Cirrhosis in Patients With Chronic Hepatitis C Virus Infection
Fasiha Kanwal et al.
GASTROENTEROLOGY (2011)
A Prospective Study of the Rate of Progression in Compensated, Histologically Advanced Chronic Hepatitis C
Jules L. Dienstag et al.
HEPATOLOGY (2011)
An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases
Marc G. Ghany et al.
HEPATOLOGY (2011)
Review article: specifically targeted anti-viral therapy for hepatitis C - a new era in therapy
C. M. Lange et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2010)
Liver Transplantation in the United States, 1999-2008
P. J. Thuluvath et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2010)
Integrating HIV Screening into Routine Health Care in Resource-Limited Settings
Ingrid V. Bassett et al.
CLINICAL INFECTIOUS DISEASES (2010)
HCV carriers with normal alanine aminotransferase levels: Healthy persons or severely ill patients? Dealing with an everyday clinical problem
Claudio Puoti et al.
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2010)
Albinterferon Alfa-2b Was Not Inferior to Pegylated Interferon-α in a Randomized Trial of Patients With Chronic Hepatitis C Virus Genotype 2 or 3
David R. Nelson et al.
GASTROENTEROLOGY (2010)
Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease Progression
Gary L. Davis et al.
GASTROENTEROLOGY (2010)
Outcome of Sustained Virological Responders With Histologically Advanced Chronic Hepatitis C
Timothy R. Morgan et al.
HEPATOLOGY (2010)
Attribution of Hepatitis C Virus Seroconversion Risk in Young Injection Drug Users in 5 US Cities
Holly Hagan et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
Hepatitis C-associated hepatocellular carcinomas in non-cirrhotic livers
Matthew M. Yeh et al.
MODERN PATHOLOGY (2010)
The effects of hepatitis C recurrence on health-related quality of life in liver transplant recipients
Hillary Bownik et al.
LIVER INTERNATIONAL (2010)
Survival and Cost-Effectiveness Analysis of Competing Strategies in the Management of Small Hepatocellular Carcinoma
Willscott E. Naugler et al.
LIVER TRANSPLANTATION (2010)
Predicting Mortality Risk in Patients With Compensated HCV-Induced Cirrhosis: A Long-Term Prospective Study
Savino Bruno et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2009)
Diagnosis, Management, and Treatment of Hepatitis C: An Update
Marc G. Ghany et al.
HEPATOLOGY (2009)
Public Health Impact of Antiviral Therapy for Hepatitis C in the United States
Michael L. Volk et al.
HEPATOLOGY (2009)
Effect of Hepatitis C Virus and Its Treatment on Survival
Adeel A. Butt et al.
HEPATOLOGY (2009)
Validity of FibroScan values for predicting hepatic fibrosis stage in patients with chronic HCV infection
Ryosuke Takemoto et al.
JOURNAL OF DIGESTIVE DISEASES (2009)
The disposition of hepatitis C antibody-positive patients in an urban hospital
B. Putka et al.
JOURNAL OF VIRAL HEPATITIS (2009)
Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection
John G. McHutchison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Meta-Regression of Hepatitis C Virus Infection in Relation to Time Since Onset of Illicit Drug Injection: The Influence of Time and Place
Holly Hagan et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2008)
Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysis
J. Thompson Coon et al.
BRITISH JOURNAL OF CANCER (2008)
HCV screening to enable early treatment of hepatitis C: A mathematical model to analyse costs and outcomes in two populations
A. Tramarin et al.
CURRENT PHARMACEUTICAL DESIGN (2008)
Treating Hepatitis C in the Prison Population Is Cost-Saving
Jennifer A. Tan et al.
HEPATOLOGY (2008)
Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: A meta-analysis and meta-regression
Hla-Hla Thein et al.
HEPATOLOGY (2008)
Outcomes of a hepatitis c screening program at a large urban VA Medical Center
Holly Groom et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2008)
Health-state utilities in liver disease: A systematic review
David J. McLernon et al.
MEDICAL DECISION MAKING (2008)
Limited uptake of hepatitis C treatment among injection drug users
Shruti H. Mehta et al.
JOURNAL OF COMMUNITY HEALTH (2008)
A health economic model to assess the cost-effectiveness of PEG IFN α-2a and ribavirin in patients with mild chronic hepatitis C
S. Gerkens et al.
JOURNAL OF VIRAL HEPATITIS (2007)
Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3
Mitchell L. Shiffman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Factors associated with seronegative chronic hepatitis C virus infection in HIV infection
Gabriel Chamie et al.
CLINICAL INFECTIOUS DISEASES (2007)
Peginterferon alfa-2a versus peginterferon alfa-2b as initial treatment of hepatitis C virus infection: A cost-utility analysis from the perspective of the Veterans Affairs health care system
Wei-Shi Yeh et al.
PHARMACOTHERAPY (2007)
Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States
Omana V. Nainan et al.
GASTROENTEROLOGY (2006)
The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients
Angelo Sangiovanni et al.
HEPATOLOGY (2006)
Clinical pathways for patients with newly diagnosed hepatitis C - What actually happens
WL Irving et al.
JOURNAL OF VIRAL HEPATITIS (2006)
Erythropoietic growth factors for treatment-induced anemia in hepatitis C: A cost-effectiveness analysis
BMR Spiegel et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2005)
Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin
P Ferenci et al.
JOURNAL OF HEPATOLOGY (2005)
Barriers to the treatment of hepatitis C
JA Morrill et al.
JOURNAL OF GENERAL INTERNAL MEDICINE (2005)
Estimation of utilities for chronic hepatitis C from SF-36 scores
HH Thein et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2005)
Cost-effectiveness of combination peginterferon α-2a and ribavirin compared with interferon α-2b and ribavirin in patients with chronic hepatitis C
SD Sullivan et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2004)
Screening in brief intervention trials targeting excessive drinkers in general practice: systematic review and meta-analysis
A Beich et al.
BMJ-BRITISH MEDICAL JOURNAL (2003)
Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population
JA Salomon et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Predicting progression to cirrhosis in chronic hepatitis C virus infection
AJ Freeman et al.
JOURNAL OF VIRAL HEPATITIS (2003)
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
MW Fried et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Comparison of second- and third-generation enzyme Immunoassays for detecting antibodies to hepatitis C virus
M Abdel-Hamid et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2002)
Assessing health-related quality of life pre- and post-liver transplantation: A prospective multicenter study
J Ratcliffe et al.
LIVER TRANSPLANTATION (2002)
Cost effectiveness of screening for hepatitis C virus in asymptomatic, average-risk adults
ME Singer et al.
AMERICAN JOURNAL OF MEDICINE (2001)
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
MP Manns et al.
LANCET (2001)
Influence of hepatitis C status on alcohol consumption in opiate users in treatment
M McCusker
ADDICTION (2001)
分享论文
